DIFF Events | Children’s hand, foot, and mouth disease is entering a high incidence period. The $8900 hand, foot, and mouth disease drug screening system is open for free trial applications in the domestic market for the first time!

Hand, foot and mouth disease has entered a high incidence stage, and children are generally susceptible to it
Hand, foot and mouth disease is a common infectious disease in children, which is generally susceptible to children under the age of 5. Summer and autumn are the high incidence seasons. Hand, foot, and mouth disease can cause fever, rashes and ulcers on the hands, feet, mouth, and other areas. In rare cases, children can also develop complications such as myocarditis, pneumonia, and viral encephalitis.
The infection caused by enterovirus EV71 is the main cause of severe infections and even deaths from hand, foot, and mouth disease. In terms of prevention, the EV71 vaccine is a common means of preventing hand, foot, and mouth disease; At present, there are no specific drugs or treatment methods for the treatment side. The main approach is to isolate patients and use other antiviral drugs such as ribavirin and ganciclovir for symptomatic treatment.
The application of viral protease inhibitor drugs is particularly important for blocking the process of viral assembly and preventing the occurrence of other complications. The current drug discovery cannot balance convenience and accuracy. Although the results of in vivo/cellular level screening are accurate, the operation is not convenient. Non cellular level experiments, although easy to operate, are prone to false positives, cannot simulate the natural process of virus infection, and are prone to missed screening. The industry urgently needs a positive screening method at the cellular level that does not require the involvement of live viruses to assist in the development of new drugs.
The best antiviral drug screening platform
The protease inhibitor screening system first developed by Defu Runsi Biotechnology has a milestone advantage in the field of early drug discovery and is the next generation of protease inhibitor screening system!
In the field of antiviral drug screening, in addition to the protease inhibitor screening system introduced earlier, Difu Runsi Biotechnology has also developed corresponding drug screening systems for preclinical drug discovery of different viruses to conduct drug efficacy evaluations at the cellular and animal levels for other viruses.
Cell level efficacy evaluation service scope:
1. Respiratory virus: Influenza virus (H1N1) H3N2、B-Yamagata、B-Victoria）、 Parainfluenza virus (types 1 and 3), respiratory syncytial virus (A2, B1), rhinovirus (types 1A, 57), adenovirus
2. Coronavirus: COVID-19 (pseudovirus), B coronavirus, 229E strain
3. Retrovirus: human T-cell virus, HIV
4. Enterovirus: Enterovirus 71, Enterovirus D68, Coxsackie virus (A2 A6 A9 A10, B1-B5), poliovirus that can cause polio
5. Herpesvirus: Herpes simplex virus (HSV-1)
6. Arbovirus: Dengue virus (DENV-1, 2, 3, 4), Japanese encephalitis virus/Japanese encephalitis virus, etc
7. Hepatitis virus: Hepatitis C virus
8. Human calicivirus: Norovirus
9. False viruses (with high biosafety requirements): Sindbis false virus, Chikungunya fever false virus, Ebola false virus, Marburg false virus, Chapare false virus, Sabia false virus, Machupo false virus, Luyo false virus, Rabies false virus, etc
10. Other animal viruses: feline calicivirus, feline herpesvirus, avian infectious bronchitis virus, porcine epidemic diarrhea virus, African swine fever virus, porcine reproductive respiratory syndrome virus, foot-and-mouth disease virus, feline infectious peritonitis virus, etc
In addition to the virus types that can be screened above, there is also a one-on-one solution for screening antiviral drugs for other virus types.
Animal level efficacy evaluation service scope:
Based on the negative pressure P2 level experimental animal platform (non GLP), the company can conduct experiments such as constructing P2 virus animal infection models and animal live imaging, including evaluation of antiviral drug efficacy in animals, evaluation of animal model vaccine efficacy, and evaluation of oncolytic virus efficacy.
The protease inhibitor screening system of Difu Runsi Biotechnology can utilize patented technology to develop a protease inhibitor screening system for all viruses.
To protect public health, assist in the early development of drugs, and take on more corporate social responsibility, Difu Runsi Biotechnology is open for free trial application within a limited time! At present, the system has been launched and sold in North America, with an official website (shop. diff biotech. com) selling for $8900.
In the previous activities, we received the attention of researchers from universities and institutions in Chinese Mainland, such as Peking University Third Hospital, West Lake University, China Pharmaceutical University, Shenzhen Bay Laboratory, the Chinese University of Hong Kong (Shenzhen), Southwest University, and so on. Thank you for your support for this system
The final phase of the event is currently underway, and Difu Runsi Biotechnology will carefully review the application. All applicants are requested to ensure that the application information is complete and clear, in order to pass the applicant information screening and review more quickly.
Company Introduction
Difu Runsi is a biopharmaceutical development platform dedicated to building a globally leading recombinant virus vector technology, focusing on innovative research and application of advanced technologies such as mucosal immune vaccines for major infectious diseases, antiviral drug discovery, gene therapy, oncolytic viruses, and virus vectors. The company has a professional P2 level animal experimental platform, high-throughput screening of antiviral drugs, vaccine evaluation and other technical platforms, which can provide various CRO services for innovative drug research and development enterprises, scientific research institutions, etc.